Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
Abstract: Pharmaceutical compositions containing as active compound a substance which inhibits the activity of TGF&bgr; on tumour cells of epithelial origin, for the treatment of epithelial, invasive tumour diseases which are characterized by a reversible transition of the cells from an epithelial, non-invasive state into a fibroblastoid, invasive state. The pharmaceutical composition contains a TGF&bgr; inhibitor, preferably combined with an Ras inhibitor. Process for screening substances for the treatment of epithelial, invasive tumour diseases.
Type:
Grant
Filed:
February 16, 1999
Date of Patent:
May 7, 2002
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Hartmut Beug, Martin Oft, Ernst Reichmann, Karl-Heinz Heider
Abstract: Proteinase inhibitors comprising a Kunitz domain are disclosed. The Kunitz domain comprises a sequence of amino acid residues as shown in SEQ ID NO:3, wherein the sequence is at least 80% identical to residues 6 through 56 of SEQ ID NO:2. Also disclosed are methods for making the proteinase inhibitors, and expression vectors and cultured cells that are useful within the methods. The proteinase inhibitors may be used as components of cell culture media, in protein purification, and in certain therapeutic and diagnostic applications.
Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the breast such as breast cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one BU101 polypeptide and at least one Mammaglobin polypeptide. In addition, the complex may comprise at least one polypeptide having at least 20% identity with the amino acid sequence of the BU101 polypeptide, the amino acid sequence of the Mammaglobin polypeptide, and fragments thereof.
Abstract: A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
Abstract: The present invention relates to a newly identified human carboxypeptidase. The invention also relates to polynucleotides encoding the carboxypeptidase. The invention further relates to methods using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders. The invention further relates to drug-screening methods using the carboxypeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the carboxypeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the carboxypeptidase polypeptides and polynucleotides.
Type:
Grant
Filed:
June 30, 1999
Date of Patent:
April 9, 2002
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Rosana Kapeller-Libermann, Kyle J. MacBeth, Mark Williamson
Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.
Abstract: Isolated proteins comprising the T-cell surface antigen CD97 &agr; are provided. Compositions and methods for making and detecting CD97 &agr; are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.
Type:
Grant
Filed:
August 20, 1999
Date of Patent:
April 2, 2002
Assignee:
The United States of America as represented by the Secretary
of the Department of Health and Human Services
Abstract: The present invention relates to a novel human protein called Prostate Specific Secreted Protein, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.
Abstract: The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.
Type:
Grant
Filed:
June 30, 1999
Date of Patent:
March 26, 2002
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Rosana Kapeller-Libermann, Mark Williamson
Abstract: A gene overexpressed in taxol-resistant cancer cell lines is disclosed. The gene is designated Taxol Resistance Associated Gene-3 (“TRAG-3”). At least two alternatively spliced forms of TRAG-3 exist. TRAG-3 polypeptides, TRAG-3 antibodies, and TRAG-3-related screening methods useful in drug discovery are also disclosed.
Type:
Grant
Filed:
March 26, 1999
Date of Patent:
March 26, 2002
Assignee:
The General Hospital Corporation
Inventors:
Michael V. Seiden, Zhenfeng Duan, Aynn Feller
Abstract: A method for reducing a catecholamine secretion from a cholinergically innervated, functional chromaffin body, such as a paraganglioma or hyperplasic adrenal medulla, by direct, local administration of a neurotoxin, such as a botulinum toxin.
Abstract: The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.
Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS190 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS190-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS190 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
Type:
Grant
Filed:
May 8, 2000
Date of Patent:
February 26, 2002
Assignee:
Abbott Laboratories
Inventors:
Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Edward N. Granados, Michael R. Klass, John C. Russell, Stephen D. Stroupe
Abstract: The present invention, based on the discovery of a new biological phenomena, provides methods and compositions for use in identifying agents which modulate the interaction between Survivin and polymerized tubulin or the mitotic spindles. Related methods and compositions can be used to modulate the interactions between Survivin and polymerized tubulin or the mitotic spindles, thereby modulating Survivin regulated apoptosis.
Abstract: The present invention relates to a protein containing an SRCR domain, a nucleic acid encoding such a protein and a method to produce same. The invention further relates to the use of the nucleic acid and the protein and antibodies directed against the protein.
Type:
Grant
Filed:
August 31, 1999
Date of Patent:
February 12, 2002
Assignee:
Deutsches Krebsforschungszentrum Stiftung des offentlichen
Rechts
Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
Type:
Grant
Filed:
August 11, 1998
Date of Patent:
January 15, 2002
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Pierre Coulie, Hideyuki Ikeda, Thierry Boon-Falleur
Abstract: The invention concerns an immunological process for the detection of an analyte in a sample, in particular of tumor markers wherein for the reduction of interference substances containing a peptide sequence derived from the framework regions of the variable domain of the antibodies to be detected or the antibodies used for immune therapy or scintigraphy are added to the test preparation. Furthermore, the invention concerns the use of such substances for the reduction of interference of immunoassays, a suppressive agent and a process for the reduction of interference of immunoassays by the substances mentioned.
Type:
Grant
Filed:
June 25, 1999
Date of Patent:
December 18, 2001
Assignee:
Roche Diagnostics GmbH
Inventors:
Sabine Nussbaum, Ellen Moessner, Helmut Lenz, Gerald Praast
Abstract: Tolerance of the immune system for self differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i.e., the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen, provided that therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example, a human differentiation antigen expressed in insect or other non-human host cells can be used to stimulate an immune response to the differentiation antigen in a human subject. Second, the therapeutic differentiation antigen may be a mutant form of a syngeneic differentiation antigen, for example a glycosylation mutant.
Type:
Grant
Filed:
May 21, 1999
Date of Patent:
December 11, 2001
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Alan N. Houghton, Clarissa Naftzger, Setaluri Vijayasaradhi
Abstract: Novel AIP-6 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length AIP-6 proteins, the invention further provides isolated AIP-6 fusion proteins, antigenic peptides and anti-AIP-6 antibodies. The invention also provides AIP-6 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a AIP-6 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.